Deals Of The Week: AstraZeneca/Regulus, Biogen Idec/Regulus, Pfizer/AstraZeneca, Elan/Neotope
Next-wave patient-based research pioneer PatientsLikeMe struck an alliance with Merck to “evaluate the impact of psoriasis on patients and to inform a novel approach to improving outcomes.”
You may also be interested in...
AstraZeneca Taps Regulus For microRNA Drug Development
Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.
Beyond Bapi: Alzheimer’s Pipeline Runs Deep
With the failure of the second of four Janssen-led Phase III trials testing bapineuzumab, partners Janssen and Pfizer have elected to discontinue the bapineuzumab I.V. clinical development program. Nonetheless, the anti-amyloid-beta approach is still alive, as the field turns to early, pre-symptomatic intervention.
Claritin Liqui-Gels' Label ‘Refresh’ Loses Blue Sky
Changes replace blue background used across Claritin line with white above navy blue waves. Brand’s still printed in white text, but in letters with blue shadow; other package-front text is in red or green instead of yellow.